Hendy Pharmaceuticals (301211.SZ) released its report for the first quarter of 2024, achieving operating income of 1.3 during the reporting period...
According to the Zhitong Finance App, Hendi Pharmaceutical (301211.SZ) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 138 million yuan, a year-on-year decrease of 28.57%. Net profit attributable to shareholders of listed companies was 37.3816 million yuan, a year-on-year decrease of 6.37%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 36.5536 million, a year-on-year decrease of 8.83%.